Proceeds to fund global Phase 3 registration program for the company's lead product candidate, Obexelimab, and support the clinical development of other pipeline programsSeries B equity financing led by
Biotechnology company CAMP4 Therapeutics has closed a $100m Series B round to progress its lead regRNA programmes and speed up the expansion of its regRNA Actuating Platform.